What is the role for Xpert® MTB/RIF in high-resource settings? Experience from a central London hospital
The role of Xpert® MTB/RIF for tuberculosis (TB) diagnosis remains to be clearly delineated in high-resource settings. At a London hospital, we evaluated a policy of selective assay use, with testing restricted to defined sub-groups of patients. Management was directly influenced in 30% of patients...
Gespeichert in:
| Veröffentlicht in: | The international journal of tuberculosis and lung disease 2014-11, Vol.18 (11), p.1323-1326 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1326 |
|---|---|
| container_issue | 11 |
| container_start_page | 1323 |
| container_title | The international journal of tuberculosis and lung disease |
| container_volume | 18 |
| creator | Gupta, R. K. Lawn, S. D. Booth, H. Morris-Jones, S. |
| description | The role of Xpert® MTB/RIF for tuberculosis (TB) diagnosis remains to be clearly delineated in high-resource settings. At a London hospital, we evaluated a policy of selective assay use, with testing restricted to defined sub-groups of patients. Management was directly
influenced in 30% of patients studied, including 'ruling-in' a TB diagnosis (leading to initiation of treatment for TB or for potential multidrug-resistant TB); negative assay results also helped support decisions for cessation of empirical anti-tuberculosis treatment or the safe initiation
of other treatments such as immunosuppressant drugs. The benefits and pitfalls of this assay's use within high-resource settings are discussed. |
| doi_str_mv | 10.5588/ijtld.14.0259 |
| format | Article |
| fullrecord | <record><control><sourceid>pubtec_pubme</sourceid><recordid>TN_cdi_pubmed_primary_25299865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>iuatld/ijtld/2014/00000018/00000011/art00012</ingid><sourcerecordid>iuatld/ijtld/2014/00000018/00000011/art00012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-f8256c7b9667683b73421bf908a80a9db327f9af2bece29b92cb61d5e2db66d53</originalsourceid><addsrcrecordid>eNp1kc1u1DAURiMEoqWwZIu8QWKTqa8T_60QlBYqDUKqimBnOY4941EmntoOAh6Kh-DJ8EymsMIbX1nHn33PrarngBeUCnHuN3noF9AuMKHyQXUKAmjNJcEPS40JrxsO8qR6ktIGYwIA_HF1QiiRUjB6Wvkva52RTyivLYphsMiFiL7ubMy_f6GPt2_Pb66vkB_R2q_WdbQpTNFYlGzOflyl1-jye2G9Hcuhi2GLNDJ2zFEPaBnGPpSLIe181sPT6pHTQ7LPjvtZ9fnq8vbiQ7389P764s2yNi2VuXaCUGZ4JxnjTDQdb1oCnZNYaIG17LuGcCe1I501lshOEtMx6KklfcdYT5uz6tWcu4vhbrIpq61Pxg6DHm2YkgIGmDOAlhW0nlETQ0rROrWLfqvjDwVY7e2qg10FrdrbLfyLY_TUbW3_l77XWYCXR0AnowcX9Wh8-scJIXDL28LdzFxxWGxptSlax2JFeaP8pA-PluHtZ6e-gRgBFCnTw0VO-Q0VqrdOT0NWWUe1-qkSkBL67n-hc-LcDMH7dg4LxH0BSse8L0jzB8ZptSE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1610761146</pqid></control><display><type>article</type><title>What is the role for Xpert® MTB/RIF in high-resource settings? Experience from a central London hospital</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Gupta, R. K. ; Lawn, S. D. ; Booth, H. ; Morris-Jones, S.</creator><creatorcontrib>Gupta, R. K. ; Lawn, S. D. ; Booth, H. ; Morris-Jones, S.</creatorcontrib><description>The role of Xpert® MTB/RIF for tuberculosis (TB) diagnosis remains to be clearly delineated in high-resource settings. At a London hospital, we evaluated a policy of selective assay use, with testing restricted to defined sub-groups of patients. Management was directly
influenced in 30% of patients studied, including 'ruling-in' a TB diagnosis (leading to initiation of treatment for TB or for potential multidrug-resistant TB); negative assay results also helped support decisions for cessation of empirical anti-tuberculosis treatment or the safe initiation
of other treatments such as immunosuppressant drugs. The benefits and pitfalls of this assay's use within high-resource settings are discussed.</description><identifier>ISSN: 1027-3719</identifier><identifier>EISSN: 1815-7920</identifier><identifier>DOI: 10.5588/ijtld.14.0259</identifier><identifier>PMID: 25299865</identifier><language>eng</language><publisher>Paris: International Union Against Tuberculosis and Lung Disease</publisher><subject>Adult ; Antitubercular Agents - pharmacology ; Bacterial diseases ; Biological and medical sciences ; Diagnosis ; Extra-Pulmonary ; Female ; Human bacterial diseases ; Humans ; Infectious diseases ; London ; Male ; Medical sciences ; Microbial Sensitivity Tests ; Middle Aged ; Mycobacterial ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - isolation & purification ; Nucleic Acid Amplification Techniques ; Pneumology ; Pulmonary ; Retrospective Studies ; Tuberculosis ; Tuberculosis - diagnosis ; Tuberculosis - drug therapy ; Tuberculosis - microbiology ; Tuberculosis and atypical mycobacterial infections ; Tuberculosis, Multidrug-Resistant - diagnosis ; Tuberculosis, Multidrug-Resistant - drug therapy ; Tuberculosis, Multidrug-Resistant - microbiology ; Xpert® MTB/RIF</subject><ispartof>The international journal of tuberculosis and lung disease, 2014-11, Vol.18 (11), p.1323-1326</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-f8256c7b9667683b73421bf908a80a9db327f9af2bece29b92cb61d5e2db66d53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28880474$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25299865$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, R. K.</creatorcontrib><creatorcontrib>Lawn, S. D.</creatorcontrib><creatorcontrib>Booth, H.</creatorcontrib><creatorcontrib>Morris-Jones, S.</creatorcontrib><title>What is the role for Xpert® MTB/RIF in high-resource settings? Experience from a central London hospital</title><title>The international journal of tuberculosis and lung disease</title><addtitle>Int J Tuberc Lung Dis</addtitle><description>The role of Xpert® MTB/RIF for tuberculosis (TB) diagnosis remains to be clearly delineated in high-resource settings. At a London hospital, we evaluated a policy of selective assay use, with testing restricted to defined sub-groups of patients. Management was directly
influenced in 30% of patients studied, including 'ruling-in' a TB diagnosis (leading to initiation of treatment for TB or for potential multidrug-resistant TB); negative assay results also helped support decisions for cessation of empirical anti-tuberculosis treatment or the safe initiation
of other treatments such as immunosuppressant drugs. The benefits and pitfalls of this assay's use within high-resource settings are discussed.</description><subject>Adult</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Diagnosis</subject><subject>Extra-Pulmonary</subject><subject>Female</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>London</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Mycobacterial</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Nucleic Acid Amplification Techniques</subject><subject>Pneumology</subject><subject>Pulmonary</subject><subject>Retrospective Studies</subject><subject>Tuberculosis</subject><subject>Tuberculosis - diagnosis</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis - microbiology</subject><subject>Tuberculosis and atypical mycobacterial infections</subject><subject>Tuberculosis, Multidrug-Resistant - diagnosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant - microbiology</subject><subject>Xpert® MTB/RIF</subject><issn>1027-3719</issn><issn>1815-7920</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAURiMEoqWwZIu8QWKTqa8T_60QlBYqDUKqimBnOY4941EmntoOAh6Kh-DJ8EymsMIbX1nHn33PrarngBeUCnHuN3noF9AuMKHyQXUKAmjNJcEPS40JrxsO8qR6ktIGYwIA_HF1QiiRUjB6Wvkva52RTyivLYphsMiFiL7ubMy_f6GPt2_Pb66vkB_R2q_WdbQpTNFYlGzOflyl1-jye2G9Hcuhi2GLNDJ2zFEPaBnGPpSLIe181sPT6pHTQ7LPjvtZ9fnq8vbiQ7389P764s2yNi2VuXaCUGZ4JxnjTDQdb1oCnZNYaIG17LuGcCe1I501lshOEtMx6KklfcdYT5uz6tWcu4vhbrIpq61Pxg6DHm2YkgIGmDOAlhW0nlETQ0rROrWLfqvjDwVY7e2qg10FrdrbLfyLY_TUbW3_l77XWYCXR0AnowcX9Wh8-scJIXDL28LdzFxxWGxptSlax2JFeaP8pA-PluHtZ6e-gRgBFCnTw0VO-Q0VqrdOT0NWWUe1-qkSkBL67n-hc-LcDMH7dg4LxH0BSse8L0jzB8ZptSE</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Gupta, R. K.</creator><creator>Lawn, S. D.</creator><creator>Booth, H.</creator><creator>Morris-Jones, S.</creator><general>International Union Against Tuberculosis and Lung Disease</general><general>International Union against Tuberculosis and Lung Disease</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141101</creationdate><title>What is the role for Xpert® MTB/RIF in high-resource settings? Experience from a central London hospital</title><author>Gupta, R. K. ; Lawn, S. D. ; Booth, H. ; Morris-Jones, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-f8256c7b9667683b73421bf908a80a9db327f9af2bece29b92cb61d5e2db66d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Diagnosis</topic><topic>Extra-Pulmonary</topic><topic>Female</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>London</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Mycobacterial</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Nucleic Acid Amplification Techniques</topic><topic>Pneumology</topic><topic>Pulmonary</topic><topic>Retrospective Studies</topic><topic>Tuberculosis</topic><topic>Tuberculosis - diagnosis</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis - microbiology</topic><topic>Tuberculosis and atypical mycobacterial infections</topic><topic>Tuberculosis, Multidrug-Resistant - diagnosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant - microbiology</topic><topic>Xpert® MTB/RIF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, R. K.</creatorcontrib><creatorcontrib>Lawn, S. D.</creatorcontrib><creatorcontrib>Booth, H.</creatorcontrib><creatorcontrib>Morris-Jones, S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The international journal of tuberculosis and lung disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, R. K.</au><au>Lawn, S. D.</au><au>Booth, H.</au><au>Morris-Jones, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What is the role for Xpert® MTB/RIF in high-resource settings? Experience from a central London hospital</atitle><jtitle>The international journal of tuberculosis and lung disease</jtitle><addtitle>Int J Tuberc Lung Dis</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>18</volume><issue>11</issue><spage>1323</spage><epage>1326</epage><pages>1323-1326</pages><issn>1027-3719</issn><eissn>1815-7920</eissn><abstract>The role of Xpert® MTB/RIF for tuberculosis (TB) diagnosis remains to be clearly delineated in high-resource settings. At a London hospital, we evaluated a policy of selective assay use, with testing restricted to defined sub-groups of patients. Management was directly
influenced in 30% of patients studied, including 'ruling-in' a TB diagnosis (leading to initiation of treatment for TB or for potential multidrug-resistant TB); negative assay results also helped support decisions for cessation of empirical anti-tuberculosis treatment or the safe initiation
of other treatments such as immunosuppressant drugs. The benefits and pitfalls of this assay's use within high-resource settings are discussed.</abstract><cop>Paris</cop><pub>International Union Against Tuberculosis and Lung Disease</pub><pmid>25299865</pmid><doi>10.5588/ijtld.14.0259</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1027-3719 |
| ispartof | The international journal of tuberculosis and lung disease, 2014-11, Vol.18 (11), p.1323-1326 |
| issn | 1027-3719 1815-7920 |
| language | eng |
| recordid | cdi_pubmed_primary_25299865 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Antitubercular Agents - pharmacology Bacterial diseases Biological and medical sciences Diagnosis Extra-Pulmonary Female Human bacterial diseases Humans Infectious diseases London Male Medical sciences Microbial Sensitivity Tests Middle Aged Mycobacterial Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - isolation & purification Nucleic Acid Amplification Techniques Pneumology Pulmonary Retrospective Studies Tuberculosis Tuberculosis - diagnosis Tuberculosis - drug therapy Tuberculosis - microbiology Tuberculosis and atypical mycobacterial infections Tuberculosis, Multidrug-Resistant - diagnosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - microbiology Xpert® MTB/RIF |
| title | What is the role for Xpert® MTB/RIF in high-resource settings? Experience from a central London hospital |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T13%3A43%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubtec_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20is%20the%20role%20for%20Xpert%C2%AE%20MTB/RIF%20in%20high-resource%20settings?%20Experience%20from%20a%20central%20London%20hospital&rft.jtitle=The%20international%20journal%20of%20tuberculosis%20and%20lung%20disease&rft.au=Gupta,%20R.%20K.&rft.date=2014-11-01&rft.volume=18&rft.issue=11&rft.spage=1323&rft.epage=1326&rft.pages=1323-1326&rft.issn=1027-3719&rft.eissn=1815-7920&rft_id=info:doi/10.5588/ijtld.14.0259&rft_dat=%3Cpubtec_pubme%3Eiuatld/ijtld/2014/00000018/00000011/art00012%3C/pubtec_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1610761146&rft_id=info:pmid/25299865&rft_ingid=iuatld/ijtld/2014/00000018/00000011/art00012&rfr_iscdi=true |